AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection.
about
M2e-Based Universal Influenza A VaccinesThe avian influenza vaccine Emerflu. Why did it fail?Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunityMultimeric recombinant M2e protein-based ELISA: a significant improvement in differentiating avian influenza infected chickens from vaccinated ones.Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as AdjuvantThe application of virus-like particles as vaccines and biological vehicles.A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.M2-based influenza vaccines: recent advances and clinical potential.Prospects of HA-based universal influenza vaccine.Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
P2860
Q26783493-F371B092-54C6-4837-B2CC-3EBBC40E8CFCQ30203302-DFC79D3E-DA13-4309-81B8-5FDC5A776816Q30398876-50502852-0578-4079-BAF6-6D530961F889Q34254359-38DD935D-91E9-438E-B6EE-73B66BFD8AE4Q34351598-143CE413-1E8A-47BE-ACE9-A6C239A615E8Q35772241-6EF69F81-D51F-45EC-A41B-A8BE2A122835Q36030772-EC151B02-01F2-4AFD-B022-663A39C2A5F6Q36086281-0FB8ECCE-7B31-41D6-8338-FC67BD186640Q38603912-50D4468F-86A9-4013-97AE-6FEC8ABF9BC5Q38667809-F4F952B8-BAE8-4D27-A98E-099E9387E497Q40437860-4D30CCF6-DE15-4126-8914-0F8995245CB2Q40571808-12BFFCBE-FDAD-49C0-955D-30A165E9F696Q41416400-80E00672-C06B-4E95-AD15-AE05BD15FD9BQ47159626-64F2664A-44FB-4A72-AFF9-C832868FAE4BQ47555220-57A143AA-79A2-4640-B9D8-E35A40EDE19F
P2860
AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
AS04-adjuvanted virus-like par ...... us confer improved protection.
@ast
AS04-adjuvanted virus-like par ...... us confer improved protection.
@en
AS04-adjuvanted virus-like par ...... us confer improved protection.
@nl
type
label
AS04-adjuvanted virus-like par ...... us confer improved protection.
@ast
AS04-adjuvanted virus-like par ...... us confer improved protection.
@en
AS04-adjuvanted virus-like par ...... us confer improved protection.
@nl
prefLabel
AS04-adjuvanted virus-like par ...... us confer improved protection.
@ast
AS04-adjuvanted virus-like par ...... us confer improved protection.
@en
AS04-adjuvanted virus-like par ...... us confer improved protection.
@nl
P2093
P2860
P1433
P1476
AS04-adjuvanted virus-like par ...... us confer improved protection.
@en
P2093
Hye Suk Hwang
Jong Seok Lee
Min-Chul Kim
Min-Kyoung Cho
Sang-Moo Kang
Young-Man Kwon
Young-Tae Lee
P2860
P304
P356
10.1016/J.VACCINE.2014.06.040
P407
P577
2014-06-19T00:00:00Z